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Objectives: To investigate the effect of phosphodiesterase type 5 inhibitor on urinary
continence recovery after bilateral nerve-sparing radical prostatectomy.
Methods: We analyzed data of 393 open bilateral nerve-sparing radical prostatecto-
mies carried out between 2005 and 2010. Patients who recovered urinary continence
within the first month after catheter removal (n = 52) were excluded. This resulted in 341
evaluable patients. Urinary continence recovery was defined as being completely pad
free over a period of 24 h. Patients were stratified according to postoperative daily
(n = 58; 17%), on-demand (n = 112; 32.8%) and no (n = 171; 50.1%) phosphodiesterase
type 5 inhibitor use. The effect of phosphodiesterase type 5 inhibitor use on urinary
continence was assessed using the Kaplan–Meier method. Uni- and multivariable Cox
regression analyses were used to test the association between phosphodiesterase type
5 inhibitor and urinary continence recovery after adjusting for cofounders.
Results: At a mean follow up of 36.4 months after surgery (median: 33), 288 patients
(84.5%) recovered urinary continence after bilateral nerve-sparing radical prostatectomy.
Patients who did not use phosphodiesterase type 5 inhibitor after surgery had lower
rates of urinary continence recovery at 1- and 2-year follow up as compared with
patients taking phosphodiesterase type 5 inhibitor (67.1 vs 86.7% and 76 vs 94.4%,
respectively; P < 0.001). After adjusting for all confounders, multivariable analysis
showed that phosphodiesterase type 5 inhibitor use, either on demand or daily, had a
positive impact on urinary continence recovery (P = 0.03).
Conclusions: Patients taking phosphodiesterase type 5 inhibitor have higher urinary
continence recovery rates as compared with patients left untreated after bilateral nerve-
sparing radical prostatectomy. An improvement in sphincteric and pelvic floor blood
supply might be responsible for this beneficial effect associated with the use of phos-
phodiesterase type 5 inhibitor.
Key words: nerve sparing, phosphodiesterase type 5 inhibitors, prostate cancer,
radical prostatectomy, urinary continence recovery.
Introduction
RP is a commonly used treatment option for patients with clinically localized PCa and a life
expectancy of at least 10 years.1 The most common sequelae of this procedure are UI and
ED, which significantly affect health-related quality of life after surgery.2 Such quality of
life issues are of increasing importance, as the introduction of PSA-based screening pro-
grams has contributed to a shift towards younger age and earlier PCa stage at diagnosis.3 For
these reasons, when technically feasible and oncologically indicated, a bilateral nerve-
sparing approach is carried out.4 This approach is aimed at providing an optimal oncological
outcome while aiming for maximal preservation of the anatomical structures devoted to
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both urinary and sexual function. However, a proportion of
patients still experience UI and ED after surgery, with a
significant negative impact on quality of life.2 It is well
known that administration of PDE5-I, either in a daily or on
demand fashion, can lead to an improvement in the recovery
of EF postoperatively.5,6 Previous studies have also shown
that PDE5, as well as cGMP and the cGMP-dependent
protein kinase-1, are expressed in the human lower urinary
tract, including the prostate, bladder and urethra.7–10 In par-
ticular, PDE5 is expressed within smooth muscle fibers of
supplying arteries of pelvic organs.8–10 Although these find-
ings have led to a surge of reports addressing the effect of
PDE5-I on lower urinary tract symptoms in patients suffer-
ing from benign prostatic hyperplasia,11 few data are avail-
able on the possible effects of PDE5-I on UC recovery after
BNSRP.12 Administration of PDE5-I might indeed improve
pelvic blood flow and oxygen supply, with a beneficial effect
on sphincter function. It is, however, not known if this might
impact on UC recovery after BNSRP.
The aim of the present study was to investigate the effect
of different PDE5-I administration schedules on UC recov-
ery in a large population of patients treated with retropubic
BNSRP at a single high-volume center.
Methods
The present study included 393 patients with PCa who
underwent retropubic BNSRP with or without pelvic lymph
node dissection at a single tertiary referral center between
January 2005 and August 2010. All patients had complete
preoperative clinical and functional data. Baseline EF was
assessed on the day before surgery by the EF domain of the
IIEF-EF. All patients were stratified as follows: 1–10 severe
ED, 11–16 moderated ED; 17–21 mild-to-moderate ED;
22–25 mild ED and 26 normal EF.13 Preoperative urinary
function was evaluated with the IPSS. Patients were catego-
rized according to validated scores as follows: 0–7 (no/mild
symptoms), 8–19 (moderate),20 (severe).14 BMI was pro-
spectively recorded in all patients before surgery.
Indication for neurovascular bundles preservation was
based on PCa characteristics at diagnosis (namely, cT1–T2a
disease, biopsy Gleason score equal to or less than 3 + 4,
PSA <10 ng/mL), regardless of preoperative erectile and
urinary function. All patients were treated with BNSRP
carried out by a group of seven surgeons using a standard-
ized technique. All patients were strongly recommended to
attempt sexual intercourse as soon as possible after catheter
removal and all of them were offered PDE5-I to encourage
the recovery of EF. Patients were retrospectively divided into
three groups according to the postoperative treatment:
patients not using PDE5-I (group 1), patients using a full
dose of PDE5-I on demand (group 2) and patients using
PDE5-I daily for 3–6 months starting from the first month
after surgery (group 3).
After the removal of the catheter, all patients were
strongly encouraged to start pelvic floor muscle exercise in
order to improve UC recovery after surgery.15
For the aim of the present study, patients who recovered
UC before the initiation of PDE5-I treatment (namely, at 1
month after BNSRRP) were excluded (n = 52). Further-
more, patients with postoperative biochemical recurrence of
PCa were excluded from our analyses. This resulted in an
overall studied population of 341 men.
Postoperative UC was defined as being completely pad
free over a period of 24 h.16 Patients were evaluated every 3
months during the first year after surgery, and every 6
months thereafter.
Statistical analyses
Kaplan–Meier curves assessed time to UC recovery after
surgery in the overall population, as well as according to
postoperative use and schedule of PDE5-I. The log–rank test
was used to compare the rates of UC recovery over time
among the three groups. The association between PDE5-I
use and UC recovery was also tested in univariable and
multivariable Cox regression models. Covariates consisted
of preoperative predictors of UC recovery (age at surgery,
BMI, preoperative IPSS and IIEF-EF) and pathological
characteristic of the disease (PSA at diagnosis and patho-
logical stage distribution).
Statistical analyses were carried out with SPSS (SPSS,
Chicago, IL, USA) version 17, with a two-sided significance
level set at P < 0.05.
Results
Clinical and pathological characteristics of patients included
in the study are shown in Table 1.
Mean time of catheter removal after surgery was 8.6 days
(median 8 days, range 6–15 days).
Although all patients were recommended to use PDE5-I
starting from 30 days after surgery in order to improve EF,
171 (50.2%) of them did not use any pro-erectile medication
(group 1). The remaining 170 (49.8%) decided to be treated.
Of these, 112 (65.8%) used PDE5-I on-demand (group 2),
whereas 58 (34.2%) used PDE5-I on a daily basis (group 3).
Among patients taking PDE5-I on demand, 47 (42%), 13
(11.6%) and 52 (46.4%) used tadalafil 20 mg, vardenafil
20 mg and sildenafil 100 mg, respectively. In this group of
patients, the mean number of doses taken over the entire
period of therapy was 1.4 per week. All patients treated with
daily PDE5-I used tadalafil.
At a mean follow up of 36.4 months after surgery (median
33), 288 patients (84.5%) recovered UC after BNSRP.
Overall, UC recovery rates at 1- and 2-year follow up were
77.3% and 85.9%, respectively (Fig. 1a). When patients
were stratified according to the use of PDE5-I, the 1- and
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2-year UC recovery rates were 67.1% and 76% for patients
not using PDE5-I versus 86.7% and 94.4% for patients using
PDE5-I, respectively (Fig. 1b; log–rank: P < 0.001). No sig-
nificant differences were found in the 1- and 2-year UC
recovery rates based on PDE5-I treatment administration
schedule (Fig. 1c; log–rank: P = 0.52). Table 2 shows uni-
variable and multivariable Cox regression analyses predict-
ing UC recovery after surgery. At univariable analyses, age
at surgery and PDE5-I use represented significant predictors
of UC recovery after RP (all P < 0.002). These results were
confirmed at multivariable analysis, where the use of
PDE5-I, as well as age at surgery and BMI (all P < 0.01),
was independently associated with UC recovery (P = 0.03).
Table 2 shows univariable and multivariable Cox regression
analyses predicting UC recovery after BNSRP among
patients not using any pro-erectile medication or using
Table 1 Clinical characteristics and descriptive statistics of patients included in the study
All
patients
(n = 341)
Patients not
using PDE5-I
(n = 171)
Patients using
PDE5-I
(n = 170)
P-value Patients using
PDE5-i on demand
(n = 112)
Patients using
PDE5-I daily
(n = 58)
n (%) n (%) n (%) n (%) n (%)
Age at surgery (years): <0.001
Mean (median) 61.3 (61.1) 62.8 (63) 59.8 (59.7) 60.1 (59.9) 59.1 (59.2)
Range 45.6–85.1 46.4–85.1 45.6–71.8 45.6–71.8 46.5–70.3
<60 147 (43.2) 59 (34.5) 88 (51.8) 58 (51.8) 30 (51.7)
60–69.9 165 (48.3) 89 (52) 76 (44.7) 49 (43.8) 27 (46.6)
70 29 (8.5) 23 (13.5) 6 (3.5) 5 (4.4) 1 (1.7)
BMI (kg/m2): 0.17
Mean (median) 25.6 (25.4) 25.7 (25.5) 25.4 (25.1) 25.4 (25.1) 25.6 (25.1)
Range 17.3–35.4 18.3–34.4 17.3–35.4 20.3–35.4 17.3–33.4
<25 146 (42.8) 65 (38.2) 81 (47.4) 54 (48) 27 (46.3)
25–30 177 (51.7) 94 (54.8) 83 (48.7) 54 (48) 29 (50)
>30 18 (5.5) 12 (7) 6 (3.9) 4 (4) 2 (3.7)
Total PSA at diagnosis (ng/mL): 0.06
Mean (median) 7.2 (5.9) 7.8 (6.1) 6.6 (5.7) 6.4 (5.3) 7.1 (6.2)
Range 0.6–54 0.6–54 0.6–29 0.6–29 1–28.6
Pathological stage distribution: 0.09
pT2 283 (83) 138 (80.7) 145 (85.3) 94 (83.9) 51 (87.9)
pT3a 38 (11.1) 19 (11.1) 19 (11.2) 12 (10.7) 7 (12.1)
pT3b 20 (5.9) 14 (8.2) 6 (3.5) 6 (5.4) 0 (0)
Pathological Gleason score: 0.13
2–6 171 (50.1) 78 (45.6) 93 (54.8) 62 (55.5) 31 (53.6)
7 152 (44.5) 81 (47.3) 71 (41.6) 45 (40) 26 (44.6)
8–10 18 (5.4) 12 (7.1) 6 (3.6) 5 (4.5) 1 (1.8)
Preoperative IIEF-EF: 0.001
Mean (median) 19.8 (25) 17.5 (22) 22 (27) 22 (27) 22.2 (27)
Range 1–30 1–30 1–30 1–30 1–30
1–10 (severe ED) 89 (26) 56 (32.7) 33 (19.4) 21 (18.8) 12 (20.7)
11–17 (moderate ED) 22 (6.7) 14 (8.8) 8 (4.7) 7 (6.3) 1 (1.7)
18–21 (mild to moderate ED) 16 (4.7) 12 (7) 4 (2.4) 0 (0) 4 (6.9)
22–25 (mild ED) 53 (15.2) 24 (13.5) 29 (17.1) 20 (17.8) 9 (15.5)
26 (no ED) 161 (47.4) 65 (38) 96 (56.4) 64 (57.1) 32 (55.2)
Preoperative IPSS: 0.06
Mean (median) 8.9 (7) 9.9 (8) 7.9 (6.5) 8.2 (6) 7.3 (7)
Range 0–33 0–33 0–33 0–33 0–22
0–7 184 (54.1) 84 (49.1) 100 (59.2) 64 (57.4) 36 (62.5)
8–19 120 (35.2) 62 (36.2) 58 (34.1) 38 (34.3) 20 (33.9)
20 37 (10.7) 25 (14.7) 12 (6.7) 10 (8.3) 2 (3.6)
Patients are tabulated according to the use of PDE5-I.
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PDE5-I on a daily basis. The use of PDE5-I was also a
significant predictor of UC recovery in this subcohort of
patients (P = 0.03).
Discussion
Urinary incontinence after RP remains one of the most
bothersome sequelae affecting health-related quality of life
after surgery, and affects between 1 and 25% of patients
treated with RP.17–20 Previous studies have extensively shown
that UC recovery depends on several parameters, including
the type of definition used, several pre- and postoperative
factors, as well as surgical technique.17–22 Although several
reports have tested the impact of behavioral therapy on UC
recovery,23,24 few data are available on the effect of pharma-
cological therapy on UC after RP. In this context, the use of
PDE5-I has been suggested in a small pilot study.12 The
rationale for the use of PDE5-I in improving UC recovery
might reside in increased pelvic blood flow and oxygen
supply, with a beneficial effect on sphincter function.
However, data on PDE5-I on UC recovery are scarce and
based on a very limited patient population.12
In the present study, we evaluated the impact of several
parameters on UC recovery, including postoperative PDE5-I
administration, in a large cohort of prospectively assessed
patients treated with BNSRP at a single high-volume refer-
ral center. For the purposes of the present study, we excluded
patients who recovered UC before PDE5-I treatment initia-
tion. Therefore, all patients included were still affected by
various degrees of UI when treatment with PDE5-I was
started. First, we evaluated the UC recovery rate, defined as
being completely pad free over a period of 24 h. We found
an overall 2-year UC recovery rate of roughly 86%. As
previously reported,17,25 the vast majority of patients recov-
ered UC within the first year after surgery. Second, we tested
the association between PDE5-I use and UC using Kaplan–
Meier analysis, as well as univariable and multivariable Cox
regression models. Patients using PDE5-I had significantly
higher rates of UC recovery as compared with patients left
untreated. However, no significant differences were found
between the on demand and the daily administration sched-
ule. Interestingly, administration of PDE5-I was also asso-
ciated with UC at multivariable analyses, even after
accounting for all cofounders. Remarkably, patients using
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Fig. 1 (a) Kaplan–Meier curve. Overall urinary continence
recovery rates (defined as usage of no pads) after BNSRP. (b)
Kaplan–Meier curve. Urinary continence recovery rates
according to the use of PDE5-I after BNSRP (P < 0.001). (c)
Kaplan–Meier curve. Urinary continence recovery rates
according to the PDE5-I administration schedule after BNSRP
(P < 0.001).

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PDE5-I had roughly 1.5-fold higher probability of UC
recovery as compared with patients not using PDE5-I.
These results were also confirmed when carrying out
separate analyses in a subcohort of patients not using any
pro-erectile medication or using PDE5-I chronically.
Several results of the present study are noteworthy. First,
we confirm previous preliminary data reporting a positive
effect of PDE5-I on urinary function after surgery. Gacci
et al. showed that vardenafil, especially when taken nightly,
was able to significantly improve urinary function as com-
pared with placebo in men treated with BNSRP.12 However,
despite the prospective study design, the trial was limited by
the low number of patients enrolled (n = 39). We tried to
circumvent this limitation by including a relative large pro-
spectively assessed patient population (n = 341), treated at a
high-volume center and by a large number of experienced
surgeons. Interestingly, the beneficial effect of PDE5-I
administration on UC recovery was confirmed even after
accounting for several preoperative parameters. Explana-
tions for our findings might be found in previous preclinical
research. Indeed, PDE5 has been shown to be ubiquitously
expressed in the lower urinary tract, including prostate,
urethra and bladder.10 In particular, Filippi et al. reported
that PDE5 expression was localized within the smooth
muscle fibers of blood vessels of both the human and rat
bladder.9 The role of PDE5 within these vessels was sug-
gested to be associated with vascular tone regulation. Pre-
vious animal studies have shown that acute PDE5-I
administration might lead to a reduction in vesicular-
deferential artery contractile tone and increased prostate
oxygenation.10 Thus, PDE5-I administration would lead to
vascular smooth muscle relaxation, with a consequent
vasodilatation of vessels involved in the blood supply of the
prostate, urethra and bladder neck. As it has been reported
that RP decreases membranous urethral blood flow,26 we can
speculate that PDE5 inhibition is able to counteract such
surgical induced deleterious effects by ameliorating pelvic
floor blood and oxygen supply. The association between
vascular status and UC after surgery has indirectly been
confirmed by previous retrospective clinical studies. These
reports showed an association between preoperative EF (a
proxy of vascular status) and UC after NSRP.20,21 Wille et al.
identified ED before RP as a prognostic factor for UC recov-
ery after surgery in their series of 403 patients.21
Second, we also confirmed previous findings about the
role of age and obesity on UC after surgery.18–20,22,27 Inter-
estingly, both variables can also be considered as markers of
patient vascular status. Higher age and BMI might indeed be
associated with worse pelvic vascular status, thus leading to
a reduction in sphinteric and pelvic blood flow and, conse-
quently, to lower UC recovery rates after surgery. Taken
together, all these observations seem to suggest a rationale
for increasing pelvic vascular supply after surgery in order
to improve both erectile and urinary function. Furthermore,
a recent review of prospective studies on the administration
of PDE5-I for the treatment of LUTS in patients affected by
benign prostatic hyperplasia showed that the degree of
improvement in IPSS depends on baseline IPSS, age and
BMI.28 In this context, obesity and older age are associated
Table 2 Univariable and multivariable Cox regression
analyses predicting UC recovery (defined as use of no pads)
after BNSRP and BNSRP among patients not using PDE5-I or
using PDE5-I on a daily basis
Predictors Univariable
analyses
Multivariable
analyses
HR; P-value HR; P-value
BNSRP
Age at surgery (years): –; 0.002 –; 0.01
<60 vs 70 2.3; 0.001 2.3; 0.004
60–69.9 vs 70 1.8; 0.02 1.9; 0.02
BMI (kg/m2): –; 0.09 –; 0.01
<25 vs >30 0.8; 0.17 0.6; 0.08
25–30 vs >30 1.4; 0.17 0.4; 0.07
Pathological stage distribution
OC vs non-OC disease 1.0; 0.56 1.1; 0.4
Total PSA at diagnosis 0.8; 0.99 1.0; 0.2
PDE5-I use according to
administration schedule
–; 0.001 –; 0.03
PDE5-I on-demand vs no
PDE5-I
1.5; 0.002 1.5; 0.04
PDE5-I daily vs no PDE5-I 1.6; 0.004 1.5; 0.02
Preoperative IPSS –; 0.06 –; 0.07
0–7 vs 20 1.3; 0.166 1.1; 0.5
8–19 vs 20 0.9; 0.78 0.8; 0.5
Preoperative IIEF-EF
26 vs 0–25 1.2; 0.1 1.1; 0.5
BNSRP among patients not using PDE5-I or using PDE5-I on
a daily basis
Age at surgery (years) –; 0.009 –; 0.04
<60 vs 70 2.5; 0.002 2.3; 0.01
60–69.9 vs 70 2; 0.02 1.9; 0.04
BMI (kg/m2) –; 0.3 –; 0.07
<25 vs >30 0.7; 0.2 0.5; 0.09
25–30 vs >30 0.6; 0.1 0.4; 0.08
Pathological stage distribution
OC vs non-OC disease 1.2; 0.4 1.3; 0.3
Total PSA at diagnosis 1; 0.6 1; 0.8
PDE5-I use
PDE5-I daily vs no PDE5-I 1.5; 0.01 1.5; 0.03
Preoperative IPSS –; 0.07 –; 0.1
0–7 vs 20 1.4; 0.3 1.2; 0.5
8–19 vs 20 0.9; 0.8 0.9; 0.5
Preoperative IIEF-EF
26 vs 0–25 0.9; 0.4 1; 0.9
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with a reduction of testosterone serum levels,29,30 which
could in turn decrease the expression of PDE5,31,32 reducing
the usefulness of PDE5-I administration in this group of
patients.
Despite several strengths, the present study was limited
by its retrospective design. Also, the use of PDE5-I might
have been influenced by patient and surgeon discussion
about possible treatment options and expectations, thus
potentially introducing a patient selection bias in the analy-
ses. Patients who decided to use PDE5-I after surgery were
younger and had lower rates of ED preoperatively. Even if
such differences in the mentioned variables have been
accounted for in multivariable models, we cannot exclude
that other unmeasured variables might have influenced the
results of our analyses. In this context, it is possible that
patients using PDE5-I might reflect a subgroup of patients
that are more motivated to reach functional recovery after
BNSRP. Unfortunately, the degree of urinary incontinence
after surgery (before treatment initiation) was not collected
in our database. It cannot be excluded that those patients that
used PDE5-I might have had a lower degree of UC in the
immediate postoperative period. Furthermore, at multivari-
able analysis preoperative IPSS was borderline significant
for the prediction of UC recovery after surgery. The use of
specific questionnaires for prostate cancer (i.e. UCLA-PCI)
for the quantification of urinary function and bother could
be significantly associated with the recovery of UC after
BNSRP.33 However, these data are not available for our
patients.
Finally, all patients were treated with BNSRP at a high-
volume center by experienced surgeons. Therefore, the
present results could differ from those derived from other
clinical settings. Despite these limitations, the present study
represents the only large retrospective report testing the
association between PDE5-I administration and UC recov-
ery in a population of patients treated with BNSRP.
In conclusion, the use of PDE5-I significantly improved
UC recovery after BNSRP regardless of the treatment
administration schedule. As PDE5 is ubiquitously expressed
in the lower urinary tract, the beneficial effect of PDE5-I on
UC recovery might reside on increased pelvic blood flow
and oxygen supply, with a beneficial effect to sphincter
function. However, well conducted, prospective randomized
trials are required to confirm these preliminary, retrospective
findings.
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Editorial Comment
Editorial Comment to Postoperative phosphodiesterase type
5 inhibitor administration increases the rate of urinary
continence recovery after bilateral nerve-sparing
radical prostatectomy
The authors investigated the effects of phosphodiesterase
type 5 inhibitors (PDE5-I) on urinary continence recovery
after bilateral nerve-sparing radical prostatectomy (BNSRP)
in a retrospective study on 393 men.1 They concluded that
men taking PDE5-I had higher continence recovery rates as
compared with those untreated after BNSRP, suggesting that
an improvement in sphincteric and pelvic floor blood supply
could be responsible for this PDE5-I dependent effect.
The present article’s strength is the large population of
the study, recruited in a single tertiary referral center for
prostate cancer, investigated preoperatively with a detailed
data setting (including baseline International Prostate
Symptoms Score [IPSS] and Body Mass Index [BMI]),
treated exclusively with BNSRP, managed with short cath-
eterization time (median 8 days) and with subsequent stand-
ardized muscle exercise to improve continence recovery
without hormone manipulation for postoperative biochemi-
cal failure, and followed up for 3 years. The few limits of
this study are the absence of a grading of severity of post-
prostatectomy urinary incontinence (such as “No pad”, “1
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